Femasys (FEMY) Share-based Compensation (2020 - 2026)
Femasys' (FEMY) quarterly Share-based Compensation came in at $210820.0 in Q2 2026, down 95.21% on a YoY basis from $4.4 million in Q2 2025, and down 93.52% quarter-over-quarter from $3.3 million in Q1 2026.
Analysis
Femasys (FEMY) Share-based Compensation (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported Share-based Compensation for 7 consecutive years, with $210820.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation fell 95.21% year-over-year to $210820.0; the trailing twelve-month figure through Jun 2026 stood at $411386.0 (down 90.65% YoY), and the FY2025 full-year result was $3.8 million, up 28.79% from the prior year.
- Share-based Compensation eased to $210820.0 in Q2 2026 per FEMY's latest filing, from $3.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.4 million in Q2 2025 and bottomed at $63445.0 in Q4 2022.
- Historically, Share-based Compensation has averaged $1.9 million across 5 years, with a median of $1.0 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Share-based Compensation jumped 1218.8% in 2022, then plunged 95.21% in 2026.
- Over 5 years, Share-based Compensation stood at $63445.0 in 2022, then jumped by 3177.28% to $2.1 million in 2023, then slumped by 93.55% to $134143.0 in 2024, then tumbled by 50.48% to $66423.0 in 2025, then surged by 217.39% to $210820.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $210820.0, $3.3 million, and $66423.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.02 Bn | 176.42 Bn | 7.27 Bn | 168.00 Mn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 67.10 Mn |
| 3 | Medtronic | 117.91 Bn | 109.10 Bn | 6.34 Bn | 125.00 Mn |
| 4 | Stryker | 105.64 Bn | 102.17 Bn | 4.50 Bn | 7.00 Mn |
| 5 | Boston Scientific | 64.99 Bn | 64.45 Bn | 3.85 Bn | 61.00 Mn |
| 6 | Edwards Lifesciences | 49.92 Bn | 45.67 Bn | 1.35 Bn | 42.20 Mn |
| 7 | Alcon | 33.23 Bn | 31.78 Bn | 1.68 Bn | 42.00 Mn |
| 8 | Dexcom | 32.10 Bn | 30.16 Bn | 830.00 Mn | 39.00 Mn |
| 9 | Steris | 20.83 Bn | 20.35 Bn | 684.20 Mn | 12.80 Mn |
| 10 | Femasys | 9.33 Mn | 7.89 Mn | 189,391.00 | 210,820.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 210,820.00 |
| Mar 31, 2026 | 3.25 Mn |
| Dec 31, 2025 | 66,423.00 |
| Sep 30, 2025 | 4.33 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 4.39 Mn |
| Dec 31, 2024 | 134,143.00 |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Sep 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 886,495.00 |
| Dec 31, 2022 | 63,445.00 |
| Sep 30, 2022 | 971,573.00 |
| Jun 30, 2022 | 950,606.00 |
| Mar 31, 2022 | 955,997.00 |
| Dec 31, 2021 | 22,885.00 |
| Sep 30, 2021 | 696,163.00 |
| Jun 30, 2021 | 699,636.00 |